ABL1 and breast carcinoma: We first determined whether ABL kinase inhibitors currently used in the clinic affect the invasive properties of three TN breast cancer cell lines (MDA-MB 231, BT-549, and MDA-MB 468) and of transformed cells the reference model cell line 3T3 SrcY527F.